Abstract:Adenosine is an evolutionary ancient metabolic regulator linking energy state to physiologic processes, including immunomodulation and cell proliferation. Tumors create an adenosine-rich immunosuppressive microenvironment through the increased release of ATP from dying and stressed cells and its ectoenzymatic conversion into adenosine. Therefore, the adenosine pathway becomes an important therapeutic target to improve the effectiveness of immune therapies. Prior research has focused largely on the two major ectonucleotidases, ectonucleoside triphosphate diphosphohydrolase 1/cluster of differentiation (CD)39 and ecto-5'-nucleotidase/CD73, which catalyze the breakdown of extracellular ATP into adenosine, and on the subsequent activation of different subtypes of adenosine receptors with mixed findings of antitumor and protumor effects. New findings, needed for more effective therapeutic approaches, require consideration of redundant pathways controlling intratumoral adenosine levels, including the alternative NAD-inactivating pathway through the CD38-ectonucleotide pyrophosphatase phosphodiesterase (ENPP)1-CD73 axis, the counteracting ATP-regenerating ectoenzymatic pathway, and cellular adenosine uptake and its phosphorylation by adenosine kinase. This review provides a holistic view of extracellular and intracellular adenosine metabolism as an integrated complex network and summarizes recent data on the underlying mechanisms through which adenosine and its precursors ATP and ADP control cancer immunosurveillance, tumor angiogenesis, lymphangiogenesis, cancer-associated thrombosis, blood flow, and tumor perfusion. Special attention is given to differences and commonalities in the purinome of different cancers, heterogeneity of the tumor microenvironment, subcellular compartmentalization of the adenosine system, and novel roles of purine-converting enzymes as targets for cancer therapy. Significance Statement The discovery of the role of adenosine as immune checkpoint regulator in cancer has led to the development of novel therapeutic strategies targeting extracellular adenosine metabolism and signaling in multiple clinical trials and preclinical models. Here we identify major gaps in knowledge that need to be filled to improve the therapeutic gain from agents targeting key components of the adenosine metabolic network and, on this basis, provide a holistic view of the cancer purinome as a complex and integrated network.

SAM transmethylation pathway and adenosine recycling to ATP are essential for systemic regulation and immune response

Methyl-Metabolite Depletion Elicits Coordinated Responses to Support Heterochromatin Stability and Epigenetic Persistence

A Metabolic Function for Phospholipid and Histone Methylation.

Adenosine production: a common path for mesenchymal stem-cell and regulatory T-cell-mediated immunosuppression

A sequential, RNA-derived, modified adenosine pathway safeguards cellular metabolism

S-Adenosylmethionine (SAM) diet promotes innate immunity via histone H3K4me3 complex

Adenosine deamination sustains dendritic cell activation in inflammation.

A bifunctional salvage pathway for two distinct S‐adenosylmethionine by‐products that is widespread in bacteria, including pathogenic Escherichia coli

The immunomodulatory function of adenosine in sepsis

Adenine is an anti-inflammatory metabolite found to be more abundant in M-CSF over GM-CSF-differentiated human macrophages

Extracellular adenosine metabolism in immune cells in melanoma

Novel Pathway of Adenosine Generation in the Lungs from NAD+: Relevance to Allergic Airway Disease

A Novel N6-Deoxyadenine Methyltransferase METL-9 Modulates C. Elegans Immunity Via Dichotomous Mechanisms

The comprehensive interactomes of human adenosine RNA methyltransferases and demethylases reveal distinct functional and regulatory features

A novel N 6 -Deoxyadenine methyltransferase METL-9 modulates C. elegans immunity via dichotomous mechanisms

Progress on &Amp;lt;italic&gt;n&lt;/italic&gt;&lt;sup&gt;6&lt;/sup&gt;-Methyladenosine Regulation of Immune Homeostasis

Profiling the compendium of changes in Saccharomyces cerevisiae due to mutations that alter availability of the main methyl donor S-Adenosylmethionine

Adenosine Primes Resting Stage Dendritic Cells Before Their Activation.

S-adenosylmethionine metabolism buffering is regulated by glycine N-methyltransferase decrease via nuclear ubiquitin-proteasome system

One-Carbon Metabolism Supports S-Adenosylmethionine and Histone Methylation to Drive Inflammatory Macrophages.

ATP and Adenosine Metabolism in Cancer: Exploitation for Therapeutic Gain